Treatment of Adult Allergic Asthma Patients with MEMP1972A

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-003997-10

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objectives of this study are to evaluate the efficacy and safety of MEMP1972A in adult patients with allergic asthma inadequately controlled despite high dose inhaled corticosteroids ( ICS) (≥ 400 μg/day total daily dose of fluticasone propionate [FP] or equivalent) and a second controller after 36 weeks of treatment.


Critère d'inclusion

  • Allergic asthma